Dr Lalith Seneviratne

Dr Lalith Seneviratne has served as a Consultant Medical Oncologist within the National Health Service for the past ten years, establishing a reputation as a seasoned clinical oncology specialist. His career is marked by a demonstrated history of delivering high‑quality care across hospital and broader health‑care settings, underpinned by expertise in oncology, healthcare information technology, health‑care management, and internal medicine. He holds an ESMO certification in Medical Oncology from the European Society for Medical Oncology, reflecting a commitment to maintaining the highest standards of clinical competence. Throughout his tenure, Dr. Seneviratne has integrated cutting‑edge information‑technology solutions into routine practice, optimizing patient pathways and data‑driven decision‑making. In his current role, Dr Seneviratne manages a diverse oncology caseload that includes gynaecological malignancies, upper gastrointestinal cancers, and early and advanced breast cancers and Germ Cell tumours. He leads multidisciplinary team (MDT) discussions, coordinates complex treatment plans, and ensures that patients receive personalized, evidence‑based therapies. His clinical responsibilities extend to supervising oncology trainee doctors, resident doctors, participating in clinical governance, and contributing to morbidity and mortality (M&M) reviews. By blending rigorous clinical acumen with a patient‑centred approach, Dr. Seneviratne consistently improves outcomes for a broad spectrum of cancer patients within the NHS framework.

Dr Seneviratne’s clinical interests are centred on malignancies that pose significant therapeutic challenges, namely early and advanced breast cancer, gynaecological cancers, oesophageal and stomach cancers, and germ‑cell tumours. He remains actively engaged in refining diagnostic algorithms and treatment pathways for these disease groups, emphasizing the integration of novel systemic therapies and advanced surgical techniques. His focus on breast and gynaecological cancers is driven by a commitment to enhancing survivorship and quality of life, particularly through the adoption of precision‑medicine strategies. Beyond direct patient care, Dr Seneviratne translates his clinical interests into active participation in numerous international clinical trials as mentioned under research interests. He has a great track record of being Principal Investigator as well as Co-Investigator for a number of practice changing clinical trials which has helped to improve cancer care to what it is today. This dual engagement—clinical practice coupled with trial leadership—enables him to bring emerging therapeutic options swiftly to his patients while advancing the scientific understanding of these cancers.

A prolific investigator, Dr Seneviratne is currently the Principal Investigator for several high‑impact trials, including TROFUSE‑032, CAMBRIA‑2, ASPEN‑09 (breast cancer), RODEO, DESTNY Ovarian‑01, and the Bluestar endometrial trial. He also serves as Co‑Investigator on studies such as Dynasty‑02, TROFUSE‑010/011, and the THREE PILLARS trial. His earlier research portfolio includes leadership of the SARONG trial, CAReS Study, Domenica trial, and multiple UK‑based cancer investigations (e.g., ICON‑8B, ISARIC, Keynote‑811). Dr. Seneviratne’s extensive experience as Sub‑PI during his registrar years at the Royal Marsden Hospital further highlights his depth of involvement across the translational research spectrum.

Dr Seneviratne regularly teaches medical students, residents, clinical fellows and registrars, acting as both Clinical and Educational Supervisor. He mentors trainees in oncology practice, research methods, and trial participation, while also providing focused training for nursing staff on chemotherapy delivery. This integrated approach ensures a well trained, multidisciplinary cancer care team.

Dr Seneviratne’s scholarly output reflects a focus on real‑world outcomes and surgical innovations in oncology. Notable publications include a multicentre UK review of nivolumab monotherapy in mismatch‑repair‑deficient metastatic endometrial cancer (ScienceDirect), an analysis linking changes in surgical paradigm to improved survival in carcinosarcoma patients (Journal of Obstetrics and Gynaecology), and a study on the impact of PARP‑inhibitor maintenance therapy in high‑grade serous tubo‑ovarian cancers (MDPI). Additional work explores ultra‑radical surgical approaches in gynecologic oncology (International Journal of Gynecological Cancer) and comparative effectiveness of FLOT versus ECX regimens, among other locally published retrospective analyses.

5

Dr Seneviratne has demonstrated strong leadership in oncology service development. At the Southwest Birmingham Hospital NHS Trust, he instituted the Carcinoma of Unknown Primary Site Multidisciplinary Team Meetings from the ground up, fulfilling a critical NHS England requirement. He also chaired the Teenage and Young Adults Cancer MDT and led the Germ‑Cell Tumour MDT at the University Hospitals of Derby and Burton NHS Trust. His active involvement in clinical governance, morbidity and mortality reviews, and regular MDT meetings underscores his commitment to high‑quality, coordinated cancer care.